Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website

2007 HSR&D National Meeting Abstract

Printable View

National Meeting 2007

3090 — Improving Adherence with PPI Prescribing Guidelines in High-Risk NSAID Users: A Controlled “Before and After” Study of a CPRS Reminder

Spiegel BM (VA Greater Los Angeles Healthcare System; Sepulveda HSR&D COE) , Glassman P (VA Greater Los Angeles Healthcare System), Dulai G (David Geffen School of Medicine at UCLA), Shekelle P (VA Greater Los Angeles Healthcare System), Ochotorena L (VA Greater Los Angeles Healthcare System), Talley J (VA Greater Los Angeles Healthcare System), Goldzweig C (VA Greater Los Angeles Healthcare System)

Nonsteroidal anti-inflammatory drugs (NSAID) cost the VA $40 million/year. This cost is partly driven by GI side effects of NSAIDs, such as ulcer bleeding. There have been calls within VA to develop cost-effective strategies to manage NSAID users at high-risk for GI complications. Proton pump inhibitor (PPI) co-therapy in high-risk users is cost-effective, and is a widely-accepted quality performance measure. Yet only 29% of high-risk NSAID users in VA receive PPIs. We sought to compare rates of “inappropriate underuse” of PPI therapy in high-risk NSAID users before versus after deployment of a CPRS reminder across the VA Greater Los Angeles Healthcare System.

We developed a system-wide CPRS reminder to target inappropriate underuse of PPI therapy in high-risk NSAID users. The reminder identified patients on chronic (>=30 day) NSAID therapy with >=1 independent risk factor(s) for GI complications (warfarin, prednisone, multiple NSAIDs, history of ulcer, age >=65) who were not receiving PPI co-therapy. The reminder was based on social influence theory, and was designed with content and methods experts to maximize point-of-care effectiveness. The primary outcome was guideline adherence (adherence=reminder resolved by initiating PPI) during the 3 month period before versus after reminder deployment. The minimum cluster-adjusted sample size was N=676. We compared adherence between periods by chi-squared, and calculated frequency counts to summarize reasons for overriding the reminder.

There were 1113 and 949 patients in the pre and post periods, respectively. Eight percent versus 38% of patients were placed on PPIs in the pre versus post periods, respectively (p<0.01). Among the 62% not placed on PPI in the intervention period, 60% had unopened reminders, and 40% had overridden reminders. Reasons for overriding: patient refused PPI (28%), patient not on NSAID (28%), provider disagreed with recommendation (25%), patient taking non-VA source PPI (19%).

The CPRS reminder improved adherence with guidelines by 30% over baseline. The study is limited by the short time horizon and lack of randomization.

If a future randomized trial is successful, then the reminder will be presented to the Clinical Decision Support Workgroup to consider exporting across VA to help enhance the capabilities of CPRS system-wide.

Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.